OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OPKO Health, Inc. (OPK) CEO Phillip Frost on Q2 2021 Results - Earnings Call Transcript

OPKO Health (OPK) delivered earnings and revenue surprises of -250.00% and -3.31%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q2 Loss, Misses Revenue Estimates

Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline

MIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021. OPKO's senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on July 29th beginning at 4:30 p.m. Eastern time.

OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

Amarin Corporation Plc

1847 GOEDEKER INC.

IAMGOLD

OMNIQ Corp

Transocean

Wipro Limited Sponsored ADR

With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on InvestorPlace.

7 Reddit Penny Stocks About to Explode

Bionano Genomics

Invitae

The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.

Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology. AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein.

OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy

MIAMI, July 12, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA. AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein. CAMP4 has prioritized OPKO's lead AntagoNAT compound to progress into clinical trials for the treatment of Dravet syndrome.

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

MIAMI, July 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021. Management will be interviewed in a fireside chat format on Tuesday, July 13th at 8:30 a.m. Eastern time and will also be holding one-on-one virtual meetings with investors throughout the day.

OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

Clear Channel Outdoor Holdings

Cocrystal Pharma

Greenpro Capital Corp

Regulus Therapeutics

Staffing 360 Solutions

With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 Hot Penny Stocks That You Should Add to Your July Watchlist

AYRO

Borr Drilling Ltd

Camber Energy

Farmmi

My Size

Weidai Ltd - ADR

Looking for the biggest gaining penny stocks today; look no further than these 9 small-caps The post 9 Top Penny Stocks to Watch That Shot Up Big Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

9 Top Penny Stocks to Watch That Shot Up Big Today

OPKO Health's (OPK) subsidiary EirGen Pharma to develop and commercialize RAYALDEE in Greater China in collaboration with an affiliate of Nicoya Therapeutics.

OPKO Health (OPK) and Nicoya Sign RAYALDEE Deal

Adial Pharmaceuticals Inc

MediciNova

Intec Parent

vTv Therapeutics

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 10 Biotech Penny Stocks to Watch in July 2021

MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE: NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.

OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

MIAMI, June 22, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers. BioReference announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group.

BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.

OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility

OPKO Health Inc's (NASDAQ: OPK) subsidiary EirGen Pharma has agreed to develop and commercialize Rayaldee to treat secondary hyperparathyroidism in patients with stage 3/4 chronic kidney disease with Nicoya Therapeutics in Greater China. Nicoya will make an upfront payment to OPKO of $5 million and an additional $5 million payment during the first 12 months of the agreement or upon Nicoya achieving a certain predetermined development milestone.

OPKO Health, Nicoya Therapeutics Ink Rayaldee Pact For Hyperparathyroidism In Greater China

MIAMI, June 21, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of RAYALDEE® for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD). Nicoya is a leading biotechnology company incubated by 6 Dimensions Capital and its successor fund 120 Capital and other co-investors, and is focusing on the Greater China nephrology market.

OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

OPKO Health Inc's (NASDAQ: OPK) subsidiary, EirGen Pharma Ltd, has agreed to sell one of its facilities in Waterford, Ireland, to Horizon Therapeutics plc (NASDAQ: HZNP) for $65 million. The facility houses EirGen's sterile-fill-finish business.

OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon Therapeutics

MIAMI, June 17, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc (Nasdaq: HZNP) for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility houses EirGen's sterile-fill-finish business. EirGen's research and development employees who were located at the site will transition to a new facility.

OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland

OPKO Health, Inc. (OPK) CEO Phillip Frost presents at Jefferies 2021 Virtual Healthcare Conference (Transcript)

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?

Why Is OPKO Health (OPK) Down 5.6% Since Last Earnings Report?

MIAMI, May 27, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announced today that management will be participating in the Jefferies Virtual Healthcare Conference being held June 1-4, 2021. Management will be interviewed in a fireside chat on Wednesday, June 2 at 11:30 a.m. Eastern time and will also be holding one-on-one virtual meetings with investors throughout the day.

News for OPKO Health Stock (OPK)